EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSOCUG00000002988
Gene Symbol: ATP1B2
3 Cross references
274 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSOCUG00000000338
Gene Symbol: ATP1B3
3 Cross references
299 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSOCUG00000001874
Gene Symbol: ATR
2 Cross references
206 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSOCUG00000016651
Gene Symbol: AXL
2 Cross references
197 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOCUG00000005487
Gene Symbol: BRAF
2 Cross references
220 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSOCUG00000003201
Gene Symbol: BCL2L1
3 Cross references
287 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSOCUG00000011889
Gene Symbol: BCL2L10
2 Cross references
129 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSOCUG00000011026
Gene Symbol: BCL2L2
2 Cross references
64 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSOCUG00000004923
Gene Symbol: BCR
2 Cross references
274 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSOCUG00000010621
Gene Symbol: BTK
3 Cross references
206 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSOCUG00000008210
Gene Symbol: CCR9
3 Cross references
262 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSOCUG00000011835
Gene Symbol: CXCL8
3 Cross references
183 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).